Jaguar Health Co-Sponsors Pediatric Gastroenterology Conference

Jaguar Health, Inc. and its family company, Napo Pharmaceuticals, are co-sponsoring the Elite Ped-GI Congress in Abu Dhabi, UAE. This event, occurring from April 2-4, 2026, focuses on advances in pediatric gastroenterology. Jaguar is emphasizing its global development program for crofelemer, targeting rare-disease intestinal failure (IF) such as microvillus inclusion disease (MVID) and short bowel syndrome (SBS), with the market for these conditions projected to hit $8 billion by 2033.

Notably, a proof-of-concept study at Sheikh Khalifa Medical City in Abu Dhabi has shown promising results in reducing parenteral support needs in pediatric IF patients. Dr. Mohamad Miqdady, conducting the study, highlighted the significant one-year benefits for patients, which have been submitted for further evaluation at upcoming global conferences.